Clinical Trials Directory

Trials / Completed

CompletedNCT04122222

Immune Response to Influenza Vaccine in ESRD Patients

Immune Response to Influenza Vaccination in ESRD Patients Undergoing Hemodialysis vs. Hemodiafiltration

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Mahidol University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We aimed to study the immune responses to influenza vaccine in dialysis patients treated by HDF vs. HD.

Conditions

Interventions

TypeNameDescription
BIOLOGICALInfluenza vaccineA single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.

Timeline

Start date
2016-08-25
Primary completion
2018-07-20
Completion
2018-07-20
First posted
2019-10-10
Last updated
2019-10-10

Source: ClinicalTrials.gov record NCT04122222. Inclusion in this directory is not an endorsement.

Immune Response to Influenza Vaccine in ESRD Patients (NCT04122222) · Clinical Trials Directory